EP1737457A2 - Use of a sphingoid base associated with nicotinic acid or a nicotinic acid amide in the form of a depigmentation agent - Google Patents
Use of a sphingoid base associated with nicotinic acid or a nicotinic acid amide in the form of a depigmentation agentInfo
- Publication number
- EP1737457A2 EP1737457A2 EP05753773A EP05753773A EP1737457A2 EP 1737457 A2 EP1737457 A2 EP 1737457A2 EP 05753773 A EP05753773 A EP 05753773A EP 05753773 A EP05753773 A EP 05753773A EP 1737457 A2 EP1737457 A2 EP 1737457A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- nicotinic acid
- composition
- phytosphingosine
- sphingoid base
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 title claims abstract description 60
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 title claims abstract description 52
- 229960003512 nicotinic acid Drugs 0.000 title claims abstract description 32
- 235000001968 nicotinic acid Nutrition 0.000 title claims abstract description 29
- 239000011664 nicotinic acid Substances 0.000 title claims abstract description 29
- 150000003410 sphingosines Chemical class 0.000 title claims abstract description 29
- 235000005152 nicotinamide Nutrition 0.000 title claims abstract description 20
- 239000011570 nicotinamide Substances 0.000 title claims abstract description 20
- 230000035614 depigmentation Effects 0.000 title abstract description 8
- 239000003795 chemical substances by application Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 claims abstract description 52
- 238000000034 method Methods 0.000 claims abstract description 16
- 239000002537 cosmetic Substances 0.000 claims abstract description 15
- 208000000069 hyperpigmentation Diseases 0.000 claims abstract description 9
- 230000003810 hyperpigmentation Effects 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims abstract description 4
- 229940033329 phytosphingosine Drugs 0.000 claims description 18
- AERBNCYCJBRYDG-UHFFFAOYSA-N D-ribo-phytosphingosine Natural products CCCCCCCCCCCCCCC(O)C(O)C(N)CO AERBNCYCJBRYDG-UHFFFAOYSA-N 0.000 claims description 17
- AERBNCYCJBRYDG-KSZLIROESA-N phytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO AERBNCYCJBRYDG-KSZLIROESA-N 0.000 claims description 16
- 150000001408 amides Chemical class 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 12
- 229940077859 salicyloyl phytosphingosine Drugs 0.000 claims description 10
- KBHSAMYHDBBRKS-QTJGBDASSA-N 2-hydroxy-n-[(2s,3s,4r)-1,3,4-trihydroxyoctadecan-2-yl]benzamide Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@H](CO)NC(=O)C1=CC=CC=C1O KBHSAMYHDBBRKS-QTJGBDASSA-N 0.000 claims description 9
- 229960003966 nicotinamide Drugs 0.000 claims description 9
- 208000012641 Pigmentation disease Diseases 0.000 claims description 8
- 239000007854 depigmenting agent Substances 0.000 claims description 8
- 230000019612 pigmentation Effects 0.000 claims description 7
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 claims description 6
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 claims description 5
- NTMFVGXTEGZVRI-RXQQAGQTSA-N (2s,3s,4r)-2-aminooctadecane-1,3,4-triol;2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1O.CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO NTMFVGXTEGZVRI-RXQQAGQTSA-N 0.000 claims description 3
- GDKAAHDFPOWGQE-RXQQAGQTSA-N (2s,3s,4r)-2-aminooctadecane-1,3,4-triol;hydrochloride Chemical compound Cl.CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO GDKAAHDFPOWGQE-RXQQAGQTSA-N 0.000 claims description 3
- 208000031066 hyperpigmentation of the skin Diseases 0.000 claims description 3
- 229940035671 phytosphingosine hydrochloride Drugs 0.000 claims description 3
- OTKJDMGTUTTYMP-UHFFFAOYSA-N dihydrosphingosine Natural products CCCCCCCCCCCCCCCC(O)C(N)CO OTKJDMGTUTTYMP-UHFFFAOYSA-N 0.000 claims description 2
- SZUJJDLBXJCDNT-ZCNNSNEGSA-N n-[(2s,3s,4r)-1,3,4-trihydroxyoctadecan-2-yl]acetamide Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@H](CO)NC(C)=O SZUJJDLBXJCDNT-ZCNNSNEGSA-N 0.000 claims description 2
- OTKJDMGTUTTYMP-ZWKOTPCHSA-N sphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO OTKJDMGTUTTYMP-ZWKOTPCHSA-N 0.000 claims description 2
- 206010040829 Skin discolouration Diseases 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 16
- 235000019160 vitamin B3 Nutrition 0.000 description 15
- 239000011708 vitamin B3 Substances 0.000 description 15
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 7
- LBQIJVLKGVZRIW-ZDUSSCGKSA-N glabridin Chemical compound C1([C@H]2CC3=CC=C4OC(C=CC4=C3OC2)(C)C)=CC=C(O)C=C1O LBQIJVLKGVZRIW-ZDUSSCGKSA-N 0.000 description 6
- 229940093767 glabridin Drugs 0.000 description 6
- PMPYOYXFIHXBJI-ZDUSSCGKSA-N glabridin Natural products C1([C@H]2CC=3C=CC4=C(C=3OC2)CCC(O4)(C)C)=CC=C(O)C=C1O PMPYOYXFIHXBJI-ZDUSSCGKSA-N 0.000 description 6
- LBQIJVLKGVZRIW-UHFFFAOYSA-N glabridine Natural products C1OC2=C3C=CC(C)(C)OC3=CC=C2CC1C1=CC=C(O)C=C1O LBQIJVLKGVZRIW-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000009472 formulation Methods 0.000 description 5
- -1 monobenzyl ether Chemical class 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 102000003425 Tyrosinase Human genes 0.000 description 4
- 108060008724 Tyrosinase Proteins 0.000 description 4
- 229940106189 ceramide Drugs 0.000 description 4
- 150000001783 ceramides Chemical class 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 230000003061 melanogenesis Effects 0.000 description 4
- WSSJONWNBBTCMG-UHFFFAOYSA-N 2-hydroxybenzoic acid (3,3,5-trimethylcyclohexyl) ester Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C1=CC=CC=C1O WSSJONWNBBTCMG-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- BTFJIXJJCSYFAL-UHFFFAOYSA-N icosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 210000002752 melanocyte Anatomy 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- NWVVVBRKAWDGAB-UHFFFAOYSA-N p-methoxyphenol Chemical compound COC1=CC=C(O)C=C1 NWVVVBRKAWDGAB-UHFFFAOYSA-N 0.000 description 3
- 239000002304 perfume Substances 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- RNVYQYLELCKWAN-UHFFFAOYSA-N solketal Chemical compound CC1(C)OCC(CO)O1 RNVYQYLELCKWAN-UHFFFAOYSA-N 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- HEOCBCNFKCOKBX-RELGSGGGSA-N (1s,2e,4r)-4,7,7-trimethyl-2-[(4-methylphenyl)methylidene]bicyclo[2.2.1]heptan-3-one Chemical compound C1=CC(C)=CC=C1\C=C/1C(=O)[C@]2(C)CC[C@H]\1C2(C)C HEOCBCNFKCOKBX-RELGSGGGSA-N 0.000 description 2
- ZQCIPRGNRQXXSK-UHFFFAOYSA-N 1-octadecoxypropan-2-ol Chemical compound CCCCCCCCCCCCCCCCCCOCC(C)O ZQCIPRGNRQXXSK-UHFFFAOYSA-N 0.000 description 2
- LALVCWMSKLEQMK-UHFFFAOYSA-N 1-phenyl-3-(4-propan-2-ylphenyl)propane-1,3-dione Chemical compound C1=CC(C(C)C)=CC=C1C(=O)CC(=O)C1=CC=CC=C1 LALVCWMSKLEQMK-UHFFFAOYSA-N 0.000 description 2
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 229960004308 acetylcysteine Drugs 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 229940061720 alpha hydroxy acid Drugs 0.000 description 2
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000003381 deacetylation reaction Methods 0.000 description 2
- 229940008099 dimethicone Drugs 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000004299 exfoliation Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 229940075529 glyceryl stearate Drugs 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000008099 melanin synthesis Effects 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- 229960001679 octinoxate Drugs 0.000 description 2
- 229940100460 peg-100 stearate Drugs 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229940078491 ppg-15 stearyl ether Drugs 0.000 description 2
- 239000003223 protective agent Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 2
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- ILCOCZBHMDEIAI-UHFFFAOYSA-N 2-(2-octadecoxyethoxy)ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCO ILCOCZBHMDEIAI-UHFFFAOYSA-N 0.000 description 1
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 1
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- ICIDSZQHPUZUHC-UHFFFAOYSA-N 2-octadecoxyethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCO ICIDSZQHPUZUHC-UHFFFAOYSA-N 0.000 description 1
- ZSNLEVJATWJBLU-UHFFFAOYSA-N 2-tert-butyl-2-methoxy-1,3-diphenylpropane-1,3-dione Chemical compound C=1C=CC=CC=1C(=O)C(C(C)(C)C)(OC)C(=O)C1=CC=CC=C1 ZSNLEVJATWJBLU-UHFFFAOYSA-N 0.000 description 1
- UTCWESKNHLBRDD-UHFFFAOYSA-N 3-chloro-2,2,3,3-tetrafluoropropanoyl chloride Chemical compound FC(F)(Cl)C(F)(F)C(Cl)=O UTCWESKNHLBRDD-UHFFFAOYSA-N 0.000 description 1
- WYVMDJWLFVQZAL-UHFFFAOYSA-N 4-propan-2-ylbenzene-1,2-diol Chemical compound CC(C)C1=CC=C(O)C(O)=C1 WYVMDJWLFVQZAL-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 1
- 239000004251 Ammonium lactate Substances 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- DHFUFHYLYSCIJY-WSGIOKLISA-N CCCCCCCCCCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O Chemical compound CCCCCCCCCCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O DHFUFHYLYSCIJY-WSGIOKLISA-N 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- MIJPAVRNWPDMOR-ZAFYKAAXSA-N L-ascorbic acid 2-phosphate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-ZAFYKAAXSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 1
- SBLKVIQSIHEQOF-UPHRSURJSA-N Octadec-9-ene-1,18-dioic-acid Chemical compound OC(=O)CCCCCCC\C=C/CCCCCCCC(O)=O SBLKVIQSIHEQOF-UPHRSURJSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 206010036229 Post inflammatory pigmentation change Diseases 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010064127 Solar lentigo Diseases 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 229930003537 Vitamin B3 Natural products 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 1
- NWGKJDSIEKMTRX-BFWOXRRGSA-N [(2r)-2-[(3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)C1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-BFWOXRRGSA-N 0.000 description 1
- SGTYQWGEVAMVKB-NXCFDTQHSA-N [(2s,3s,4r)-2-acetamido-3,4-diacetyloxyoctadecyl] acetate Chemical compound CCCCCCCCCCCCCC[C@@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H](NC(C)=O)COC(C)=O SGTYQWGEVAMVKB-NXCFDTQHSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229940058182 aminoethylphosphinic acid Drugs 0.000 description 1
- 235000019286 ammonium lactate Nutrition 0.000 description 1
- 229940059265 ammonium lactate Drugs 0.000 description 1
- 230000003255 anti-acne Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- RZOBLYBZQXQGFY-HSHFZTNMSA-N azanium;(2r)-2-hydroxypropanoate Chemical compound [NH4+].C[C@@H](O)C([O-])=O RZOBLYBZQXQGFY-HSHFZTNMSA-N 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 150000008366 benzophenones Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- NZZIMKJIVMHWJC-UHFFFAOYSA-N dibenzoylmethane Chemical class C=1C=CC=CC=1C(=O)CC(=O)C1=CC=CC=C1 NZZIMKJIVMHWJC-UHFFFAOYSA-N 0.000 description 1
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- DLAHAXOYRFRPFQ-UHFFFAOYSA-N dodecyl benzoate Chemical compound CCCCCCCCCCCCOC(=O)C1=CC=CC=C1 DLAHAXOYRFRPFQ-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960004697 enzacamene Drugs 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 229940100242 glycol stearate Drugs 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 229940116918 octadecenedioic acid Drugs 0.000 description 1
- VTQCKDJHYPCDHH-UHFFFAOYSA-N octan-4-yl 2-methoxy-3-phenylprop-2-enoate Chemical compound CCCCC(CCC)OC(=O)C(OC)=CC1=CC=CC=C1 VTQCKDJHYPCDHH-UHFFFAOYSA-N 0.000 description 1
- FMJSMJQBSVNSBF-UHFFFAOYSA-N octocrylene Chemical group C=1C=CC=CC=1C(=C(C#N)C(=O)OCC(CC)CCCC)C1=CC=CC=C1 FMJSMJQBSVNSBF-UHFFFAOYSA-N 0.000 description 1
- 229960000601 octocrylene Drugs 0.000 description 1
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229950006451 sorbitan laurate Drugs 0.000 description 1
- 229950004959 sorbitan oleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229940098760 steareth-2 Drugs 0.000 description 1
- 229940100458 steareth-21 Drugs 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000037072 sun protection Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 229910052726 zirconium Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
Definitions
- a sphingoid base associated with nicotinic acid or an amide of nicotinic acid as depigmenting agent.
- the present invention relates to a new use of a composition
- a composition comprising a combination of at least nicotinic acid or an amide of nicotinic acid and at least one sphingoid base.
- PRIOR ART Depigmentation of the skin may be desired under various circumstances, either for a global lightening thereof, or to eliminate or attenuate spots resulting from local pigmentation disorders.
- the pigmentation of the skin is determined by the presence of melanin in the epidermis and the dermis. Melanin is produced by melanocytes located mainly in the basal layer. These melanocytes send dendritic extensions everywhere, between the keratinocytes.
- the enzyme tyrosinase is needed to produce melanin.
- This biosynthesis also called melanogenesis
- melanogenesis is a complex process which is now relatively well known.
- the pigmentation is normally uniform.
- pigmentation can be excessive locally, what is commonly called hyperpigmentation.
- Hyperpigmentation of the skin can include blemishes or disorders of the skin including freckles, senile lentigo, melasma, age spots, pigmentation due to sunburn, post-inflammatory hyperpigmentation due to l , burns, wounds, insect bites, dermatitis, and other small local pigmented lesions.
- Many cosmetic treatment methods for hyperpigmentation exist but none is completely satisfactory.
- exfoliation including chemical exfoliation, or methods having an impact on melanogenesis, using depigmenting agents.
- depigmenting agents commonly used act directly on the vitality of the epidermal melanocytes where melanogenesis takes place and / or interfere with one of the stages of melanin biosynthesis either by inhibiting one of the enzymes involved in melanogenesis, or by intercalating as an analogue. structural of one of the chemical compounds in the melanin synthesis chain, which chain can then be blocked and thus ensure depigmentation.
- Depigmenting agents can be divided into several groups: Phenolic compounds, which include in particular the following compounds: • Hydroquinone and its ethers such as monobenzyl ether, • 4-methoxyphenol, • 4-isopropylcatechol, • 4-hydroxyanisole and, • N -acetyl-4-S-cystaminylphenol, - Non-phenolic compounds, which include in particular the following compounds: • Corticosteroids, • Tretinoin, • Azelaic acid, • N-acetylcysteine (NAC), • Ascorbic acid and derivatives such as L-ascorbyl-2-phosphate and, • Kojic acid, Combinations of these compounds, among which there may be mentioned the Kligman formulation, the Pathak formulation or the Westerhof formulation.
- Phenolic compounds which include in particular the following compounds: • Hydroquinone and its ethers such as monobenzyl ether, • 4-methoxyphenol, • 4-isopropylcatechol, • 4-hydroxy
- nicotinamide or niacinamide also called vitamin PP, vitamin B3 or niacin
- Application WO 99.47114 also describes compositions essentially comprising nicotinic acid or nicotinamide as well as an intermediate or precursor of ceramides, used only for hydration of the skin and not for its depigmentation.
- sphingoid bases such as phytosphingosine and sphingosine, precursors of ceramides, are present in human skin, and studies have shown that these molecules have inhibitory properties of protein kinase C, and seem to be involved in differentiation of keratinocytes of the epidermis.
- sphingosines present in the stratum corneum and other layers of the epidermis inhibit the growth of certain undesirable microorganisms.
- Various publications describe the use of sphingosine and phytosphingosine in cosmetic and dermatological compositions.
- patent application WO 95.03028 describes sphingosine, used in a composition with a pH close to 5, to reduce the irritant effect of certain alpha-hydroxy acids.
- Patent EP 940,140 describes a cosmetic composition combining alpha-hydroxy acids and ceramides or precursors of ceramides such as phytosphingosine.
- sphingoid bases have not been found to be effective as depigrants.
- EP 919,226 relates to a cosmetic composition based on phytosphingosine salicylate capable of having anti-acne, anti-wrinkle or lightening properties. the skin.
- the composition can also contain various usual ingredients of the technique such as vitamins A, C and E, used according to their well known properties. It is also known from patent application WO 02/085362 that a composition essentially comprising nicotinic acid or an amide of nicotinic acid and a sphingoid base is useful for the treatment of keratinization disorders in human or animal dermatology .
- the subject of the invention is therefore the use of a composition comprising a combination of at least nicotinic acid or an amide of nicotinic acid and at least one sphingoid base as depigmenting agent .
- the subject of the invention is also a method of depigmentation of the skin, consisting in applying to the exposed areas a composition comprising a combination of at least nicotinic acid or an amide of nicotinic acid and at least one base. sphingoid.
- the subject of the invention is more particularly the use of a combination of at least nicotinic acid or an amide of nicotinic acid and of at least one sphingoid base to promote lightening of the skin as well as the associated cosmetic treatment method.
- a more particular subject of the invention is therefore also the use of a combination of at least nicotinic acid or an amide of nicotinic acid and at least one sphingoid base to combat hyperpigmentation of the skin as well as the associated cosmetic treatment method.
- the invention also relates to a cosmetic treatment method for the skin intended to reduce, eliminate or avoid pigmentation spots, by providing a depigmenting or lightening effect consisting in applying to the exposed areas a composition comprising a combination of minus nicotinic acid or an amide of nicotinic acid and at least one sphingoid base.
- a subject of the invention is finally the use of a combination of at least nicotinic acid or an amide of nicotinic acid and at least one sphingoid base, for the preparation of a dermatological composition intended for combating against hyperpigmentation.
- the nicotinic acid amide may preferably be nicotinamide or vitamin PP.
- the sphingoid base can be chosen from sphingosine, sphinganine, phytosphingosine, salicyloyl phytosphingosine, phytosphingosine salicylate, tetracetylphytosphingosine, N-acetyl phytosphingosine and phytosphingosine hydrochloride.
- the preferred sphingoid base is phytosphingosine, salicyloyl phytosphingosine (N-salicyloyl phytosphingosine) or phytosphingosine hydrochloride.
- the nicotinic acid, or the nicotinic acid amide can be used in an amount of 0.1 to 15% by weight relative to the total weight of the composition, and preferably from 1 to 10%.
- the sphingoid base content can vary depending on the base used, but it is generally between 0.01% and 5%, preferably between 0.05 and 2%.
- Nicotinic acid and nicotinic acid amide, especially vitamin PP, as well as the sphingoid bases used in the compositions of the present invention are generally commercially available and can be obtained by known methods from various sources. appropriate.
- the sphingoid bases can be obtained from natural sources or by chemical synthesis or by fermentation. They can also be obtained from animal or plant tissues by extraction and purification.
- the sphingoid bases used in the invention are prepared by microbial fermentation, for example from a yeast such as Pichia ciferii, and the phytosphingosine obtained in this way has the advantage of being very close to that of the human or animal skin.
- the phytosphingosine obtained from tetra-acetyl-phytosphingosine by deacetylation is used as the sphingoid base.
- the deacetylation reaction can be carried out by chemical reaction, for example by hydrolysis in basic medium, or by enzymatic reaction.
- the tests carried out on the use according to the present invention of the compositions described above have demonstrated a synergy of action, particularly between the vitamin PP and phytosphingosine, providing a potentiation of depigmenting activity.
- Vitamin PP would act mainly by a mechanism of inhibition of the transfer of melanin towards the keratinocyte while phytosphingosine would inhibit the translocation of NFkappaB after exposure to UV.
- Another depigmenting agent may be incorporated into the compositions the use of which is the subject of the present invention, a list of examples of which has been provided above in the introduction. It is also possible to combine with the compositions according to the present invention exfoliants and in particular lactic acid. All these variant compositions are also part of the invention.
- the excipients and carriers which can be used in the compositions in accordance with the present invention are those commonly used in preparations for cosmetic use, and chosen according to the form of administration used.
- gelling agents By way of example, mention may be made of gelling agents, emulsifiers, thickeners, preservatives, softeners, as well as perfumes.
- emulsifying agent from carboxyvinyl polymers of high molecular weight such as Carbopol ®, polysorbates such as those marketed under the trademark T een 20 ® or Tween 60 ®, sorbitan esters and, for example a stearate, palmitate, a sorbitan oleate or laurate (for example Arlacel ® ).
- emulsifying agents various derivatives of stearic or palmitic acid such as glycerol stearate, propylene glycol stearate, polyethylene glycol stearate, PEG 100® stearate, steareth or ceteareth, or alternatively polyglyceryl-2-sesquioleate, polyoxyethylene cetyl ether, a polyglucoside of siloxane, or an emulsifiable silicone.
- the gelling agents and thickeners are incorporated into the composition to improve the fluidity.
- the softeners can be chosen from fatty alcohols or esters, and for example products based on isostearyl alcohol or polysaccharide sorbitol sold under the brands Soothex® and Rhamnosoft®. In general, the usual softeners of the technique may be suitable in the invention.
- Protective agents against ultraviolet rays can also be added to the compositions, the use of which is the subject of the present invention.
- These protective agents can for example be hydrophilic or lipophilic UV-A and UV-B sun filters which can be chosen from benzophenone or a benzophenone derivative such as 2-hydroxy-4-methoxy-benzophenone (Eusolex® 4360) , or an ester of cinnamic acid and more particularly octyl methoxycinnamate (Eusolex® 2292), ethyl-2-hexyl methoxycinnamate (Parsol MCX®), or alternatively a cyano- ⁇ , ⁇ -di-phenylacrylate such as octocrylene (Eusolex® OCR), 4-methylbenzylidene camphor (Eusolex 6300®), and dibenzoylmethane derivatives such as 4-isopropyl dibenzoylmethane (Eusolex 8020), t
- pigments forming an anti-ultraviolet screen which can for example be chosen from titanium dioxide (amorphous or crystallized in the form rutile or anatase), zinc oxide, zirconium or aluminum.
- nanopigments of metal oxides with a particle size between 5 and 100 nm can be used.
- a solvent capable of facilitating or improving the penetration of the active principles into the skin can also advantageously be included in the compositions of the invention, and for example one can use a non-ionic amphiphilic glycerol derivative such as 1, 2-O-isopropylidene glycerol (Solketal).
- the compositions for implementing the invention can be in all the usual dosage forms suitable for dermatological or cosmetic indication, for topical application.
- compositions can be, for example, in the form of aqueous, oily or hydroalcoholic solutions, dispersions, sera, gels (aqueous, anhydrous or lipophilic), micellar lotions, hydroalcoholic lotions, spray solutions, suspensions, ionic or nonionic vesicular dispersions, liquid or semi-liquid emulsions (for example milk), solid or semi-solid.
- the emulsions can be of the oil in water (O / W) or water in oil (W / O) type, for example gels or creams.
- the compositions, the use of which is the subject of the present invention can be applied directly to the skin at the rate of one or more applications per day for a duration adapted to the duration of the affection.
- Example 1 A blind study on volunteers was carried out during the sunny period (8 volunteers per product). This study is based on a global evaluation of the color parameters of the back skin of the hands in a “before” versus “after” use mode. The products were applied to the entire hand and the effect was evaluated at the level of pre-selected pigment spots and at the level of an area free from stains (called the "control" site). Each volunteer used a sun protection cream on the hands to minimize the risk of hyperpigmentation which could appear under the influence of ultraviolet radiation linked to sunlight during the experiment. The following parameters were studied: geometry of the spots (size), melanic index on the spot and on the "control” site and, - luminance (L *) on the spot and on the "control” site. The analysis concerns the evolution of the parameters between the first and the last day of the study for the applied products. The composition of the products studied is as follows:
- Vitamin PP Depigmenting Formula 1 0 g, 0% Formula 2 5 Q. 0 Salicyloyl Phytosphingosine 0, 1% Formula 3 5 g. ⁇ Formula 4 0 o. o Arlatone dio ⁇ c Formula 5 0 ⁇ Albatin
- formula 1 is the placebo formula
- formula 2 is based on the “active base” containing vitamin PP at a concentration of 5%, in which a sphingoid base has been added, while formula 3 contains the same dose of vitamin PP without phytosphingosine.
- Formulas 4 and 5 are commercially available compositions containing listed depigmentants, namely octadecene dioic acid (Arlatone dioic) and aminoethylphosphinic acid (Albatin).
- listed depigmentants namely octadecene dioic acid (Arlatone dioic) and aminoethylphosphinic acid (Albatin).
- the results obtained show that: - For formulations 1, 2 and 3, the geometry of the spots does not change significantly over time. - The luminance (L *) of the skin increases (the color of the skin becomes lighter) at the level of the spots and at the level of the “control” zone for formula 2. - The melanic index decreases (less melanin is present) at the spot level and at the level of the "control" zone for formula 2.
- TRIO D is a depigmenting composition based on ammonium lactate, ascorbic acid and glabridin at a concentration of 0.1%.
- TRIO A includes the same active ingredients and glabridin at a concentration of 0.2%.
- Formula C of the invention contains the same concentration of glabridin, which is a compound known for its antityrosinase activity. Attempts.
- compositions being in ethanolic solution buffered to pH 6.8 containing 500 ⁇ l of tyrosine solution and 500 ⁇ l of tyrosinase solution, and the control used is identical but does not contain depigmentant.
- a blank control is identical to the control but the tyrosinase is replaced by the same amount of water.
- a blank test is prepared using the same sample of formula to be tested but by replacing the tyrosinase with the same amount of water. It is left to incubate for 1 hour in a water bath at 37 ° C protected from light and then the tubes containing the formulas tested are cooled in a cold water bath to about 18 ° C. The absorbance of the solutions is measured at 475 n in a 10 mm tank. The results are collated in the following table.
- the average inhibition rate for an amount of lmg product was obtained by averaging the measurements of each formula (3 measurements per formula) compared to an amount of product of 1 mg. It is therefore found that the formula C according to the invention has a significantly higher antityrosinase activity than the reference formulas, resulting in a greater depigmatory power. It is noted in particular that the inhibition rate is doubled compared to formula B which contains the same glabridin content. This demonstrates the effect of the combination of vitamin PP and phytosphingosine on depigmentation.
- the examples which follow relate to formulations containing an association the use of which is the subject of the present patent application. The names of the components are taken from the INCI nomenclature.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
Abstract
The invention relates to using a composition comprising an association of at least one type of nicotinic acid or nicotinic acid amide and at least one type of a sphingoid base in the form of a depigmentation agent. The use of the inventive composition makes it possible simultaneously to promote skin lightening and control a local skin hyperpigmentaton of any nature and origin. Methods for an associated cosmetic treatment and the use the association of at least one type of nicotinic acid or nicotinic acid amide and at least one type of a sphingoid base for preparing a dermatological preparation for controlling hyperpigmentation are also disclosed.
Description
Utilisation d'une base sphingoïde associée à 1 ' acide nicotinique ou un amide de 1 ' acide nicotinique à titre d'agent dépigmentant. Use of a sphingoid base associated with nicotinic acid or an amide of nicotinic acid as depigmenting agent.
La présente invention concerne une nouvelle utilisation d'une composition comprenant une association d'au moins l'acide nicotinique ou un amide de l'acide nicotinique et au moins une base sphingoïde. L' art antérieur La dépigmentation de la peau peut être souhaitée dans diverses circonstances, soit pour un éclaircissement global de celle-ci, soit pour éliminer ou atténuer des taches issues de troubles locaux de la pigmentation. La pigmentation de la peau est déterminée par la présence de mélanine dans l'épiderme et le derme. La mélanine est fabriquée par les mélanocytes situés principalement dans la couche basale. Ces mélanocytes envoient des prolongements dendritiques un peu partout, entre les kératinocytes . Il faut la présence d'une enzyme, la tyrosinase, pour produire la mélanine. Cette biosynthèse, également nommée mélanogénèse est un processus complexe qui est maintenant relativement bien connu. Ainsi, la pigmentation est normalement uniforme. Toutefois, la pigmentation peut être excessive localement, ce qu'on nomme couramment l'hyperpigmentation. L'hyperpigmentation de la peau peut inclure des défauts ou des désordres de la peau comprenant des taches de rousseur, lentigo sénile, mélasme, des taches de vieillissement, la pigmentation due à des coups de soleil, l'hyperpigmentation post-inflammatoire due à l'abrasion, les brûlures, les blessures, les morsures d'insecte, les dermatites, et autres petites lésions pigmentées locales.
De nombreuses méthodes de traitement cosmétique de l'hyperpigmentation existent mais aucune n'est complètement satisfaisante. Il existe en effet des méthodes de gommage, y compris de gommage chimique, ou encore des méthodes ayant une incidence sur la mélanogénèse, utilisant des agents dépigmentants. Les agents dépigmentants couramment utilisés agissent directement sur la vitalité des mélanocytes epidermiques où se déroule la mélanogénèse et/ou interfèrent avec une des étapes de la biosynthèse de la mélanine soit en inhibant une des enzymes impliquées dans la mélanogénèse, soit en s ' intercalant comme analogue structural d'un des composés chimiques de la chaîne de synthèse de la mélanine, chaîne qui peut alors être bloquée et ainsi assurer la dépigmentation. Les agents dépigmentants peuvent être répartis en plusieurs groupes : Les composés phénoliques, qui comprennent notamment les composés suivants : • Hydroquinone et ses éthers tels que le monobenzyl éther, • 4-méthoxyphénol, • 4-isopropylcatéchol, • 4-hydroxyanisole et, • N-acétyl-4-S-cystaminylphénol, - Les composés non phénoliques, qui comprennent notamment les composés suivants : • Corticostéroïdes, • Trétinoine, • Acide azélaique, • N-acétylcystéine (NAC) , • L'acide ascorbique et des dérivés tels que le L-ascorbyl-2-phosphate et, • L'acide Kojique,
Les associations de ces composés parmi lesquelles on peut citer la formulation Kligman, la formulation Pathak ou la formulation Westerhof. De plus, le nicotinamide ou niacinamide, également appelé vitamine PP, vitamine B3 ou encore niacine, est connu pour ses propriétés dépigmentantes. La demande WO 99.47114 décrit aussi des compositions comprenant essentiellement de l'acide nicotinique ou du nicotinamide ainsi qu'un intermédiaire ou précurseur de céramides, utilisées uniquement pour l'hydra- tation de la peau et non pour sa dépigmentation. Par ailleurs, on sait que des bases sphingoïdes telles que la phytosphingosine et la sphingosine, précurseurs de céramides, sont présentes dans la peau humaine, et des études ont montré que ces molécules ont des propriétés inhibitrices de la protéine kinase C, et semblent impliquées dans la différenciation des kératinocytes de l'épiderme. On a également observé que des sphingosines présentes dans le stratum corneum et d'autres couches de l'épiderme, inhibent la croissance de certains micro-organismes indésirables. Diverses publications décrivent l'utilisation de la sphingosine et de la phytosphingosine dans des compositions cosmétiques et dermatologiques. Par exemple, la demande de brevet WO 95.03028 décrit la sphingosine, utilisée dans une composition à pH voisin de 5, pour réduire l'effet irritant de certains alpha-hydroxy-acides. Le brevet EP 940.140 décrit une composition cosmétique associant des alpha-hydroxy-acides et des céramides ou des précurseurs de céramides tels que la phytosphingosine. Cependant, à ce jour, les bases sphingoïdes ne se sont pas révélées efficaces en tant qu'agents dépig- mentants. La demande EP 919.226 concerne une composition cosmétique à base de salicylate de phytosphingosine susceptible d'avoir des propriétés anti-acnéiques, antirides ou éclaircissantes de
la peau. La composition peut aussi contenir divers ingrédients usuels de la technique tels que des vitamines A, C et E, utilisées en fonction de leurs propriétés bien connues. Il est par ailleurs connu de la demande de brevet WO 02/085362 qu'une composition comprenant essentiellement l'acide nicotinique ou un amide d'acide nicotinique et une base sphingoïde est utile pour le traitement des troubles de la kératinisation en dermatologie humaine ou animale. En particulier, cette association, et notamment celle d'un amide d'acide nicotinique tel que la vitamine PP, et d'une base sphingoïde, est décrite comme utile dans le traitement de l'acné, notamment l'acné vulgaris, et de la dermite atopique. Par conséquent, il existe un besoin accru dans le domaine cosmétologique de trouver des méthodes alternatives de traitement de l'hyperpigmentation, et donc d'identifier des composés possédant des propriétés dépigmentantes. Les études effectuées par la demanderesse ont montré un effet synergique sur la dépigmentation en associant l'acide nicotinique ou un amide d'acide nicotinique tel que la vitamine PP, et une base sphingoïde au sein de la même composition.The present invention relates to a new use of a composition comprising a combination of at least nicotinic acid or an amide of nicotinic acid and at least one sphingoid base. PRIOR ART Depigmentation of the skin may be desired under various circumstances, either for a global lightening thereof, or to eliminate or attenuate spots resulting from local pigmentation disorders. The pigmentation of the skin is determined by the presence of melanin in the epidermis and the dermis. Melanin is produced by melanocytes located mainly in the basal layer. These melanocytes send dendritic extensions everywhere, between the keratinocytes. The enzyme tyrosinase is needed to produce melanin. This biosynthesis, also called melanogenesis, is a complex process which is now relatively well known. Thus, the pigmentation is normally uniform. However, pigmentation can be excessive locally, what is commonly called hyperpigmentation. Hyperpigmentation of the skin can include blemishes or disorders of the skin including freckles, senile lentigo, melasma, age spots, pigmentation due to sunburn, post-inflammatory hyperpigmentation due to l , burns, wounds, insect bites, dermatitis, and other small local pigmented lesions. Many cosmetic treatment methods for hyperpigmentation exist but none is completely satisfactory. There are indeed methods of exfoliation, including chemical exfoliation, or methods having an impact on melanogenesis, using depigmenting agents. The depigmenting agents commonly used act directly on the vitality of the epidermal melanocytes where melanogenesis takes place and / or interfere with one of the stages of melanin biosynthesis either by inhibiting one of the enzymes involved in melanogenesis, or by intercalating as an analogue. structural of one of the chemical compounds in the melanin synthesis chain, which chain can then be blocked and thus ensure depigmentation. Depigmenting agents can be divided into several groups: Phenolic compounds, which include in particular the following compounds: • Hydroquinone and its ethers such as monobenzyl ether, • 4-methoxyphenol, • 4-isopropylcatechol, • 4-hydroxyanisole and, • N -acetyl-4-S-cystaminylphenol, - Non-phenolic compounds, which include in particular the following compounds: • Corticosteroids, • Tretinoin, • Azelaic acid, • N-acetylcysteine (NAC), • Ascorbic acid and derivatives such as L-ascorbyl-2-phosphate and, • Kojic acid, Combinations of these compounds, among which there may be mentioned the Kligman formulation, the Pathak formulation or the Westerhof formulation. In addition, nicotinamide or niacinamide, also called vitamin PP, vitamin B3 or niacin, is known for its depigmenting properties. Application WO 99.47114 also describes compositions essentially comprising nicotinic acid or nicotinamide as well as an intermediate or precursor of ceramides, used only for hydration of the skin and not for its depigmentation. Furthermore, it is known that sphingoid bases such as phytosphingosine and sphingosine, precursors of ceramides, are present in human skin, and studies have shown that these molecules have inhibitory properties of protein kinase C, and seem to be involved in differentiation of keratinocytes of the epidermis. It has also been observed that sphingosines present in the stratum corneum and other layers of the epidermis inhibit the growth of certain undesirable microorganisms. Various publications describe the use of sphingosine and phytosphingosine in cosmetic and dermatological compositions. For example, patent application WO 95.03028 describes sphingosine, used in a composition with a pH close to 5, to reduce the irritant effect of certain alpha-hydroxy acids. Patent EP 940,140 describes a cosmetic composition combining alpha-hydroxy acids and ceramides or precursors of ceramides such as phytosphingosine. To date, however, sphingoid bases have not been found to be effective as depigrants. EP 919,226 relates to a cosmetic composition based on phytosphingosine salicylate capable of having anti-acne, anti-wrinkle or lightening properties. the skin. The composition can also contain various usual ingredients of the technique such as vitamins A, C and E, used according to their well known properties. It is also known from patent application WO 02/085362 that a composition essentially comprising nicotinic acid or an amide of nicotinic acid and a sphingoid base is useful for the treatment of keratinization disorders in human or animal dermatology . In particular, this association, and in particular that of a nicotinic acid amide such as vitamin PP, and of a sphingoid base, is described as useful in the treatment of acne, in particular acne vulgaris, and of atopic dermatitis. Consequently, there is an increased need in the cosmetics field to find alternative methods of treating hyperpigmentation, and therefore to identify compounds having depigmenting properties. The studies carried out by the applicant have shown a synergistic effect on depigmentation by combining nicotinic acid or an amide of nicotinic acid such as vitamin PP, and a sphingoid base within the same composition.
La présente invention L'invention a donc pour objet l'utilisation d'une composition comprenant une association d'au moins l'acide nicotinique ou un amide de l'acide nicotinique et d'au moins une base sphingoïde à titre d'agent dépigmentant. L'invention a encore pour objet une méthode de dépigmentation de la peau, consistant à appliquer sur les zones exposées une composition comprenant une association d'au moins l'acide nicotinique ou un amide de l'acide nicotinique et d'au moins une base sphingoïde. On parle parfois dans la littérature pour un composé utile dans le domaine cosmétique de « propriétés éclair-
cissantes » pour la peau ; dans le cadre de la présente invention, les « propriétés dépigmentantes » comprennent, outre les propriétés permettant de lutter contre l'hyperpigmentation, également ces « propriétés éclaircissantes ». Par conséquent, l'invention a plus particulièrement pour objet l'utilisation d'une association d'au moins l'acide nicotinique ou un amide de l'acide nicotinique et d'au moins une base sphingoïde pour favoriser l'éclaircissement de la peau ainsi que la méthode de traitement cosmétique associée. L'invention a donc aussi plus particulièrement comme objet l'utilisation d'une association d'au moins l'acide nicotinique ou un amide de l'acide nicotinique et d'au moins une base sphingoïde pour lutter contre l'hyperpigmentation de la peau ainsi que la méthode de traitement cosmétique associée. Autrement dit, l'invention concerne également une méthode de traitement cosmétique de la peau destinée à réduire, supprimer ou éviter les tâches de pigmentation, en procurant un effet dépigmentant ou éclaircissant consistant à appliquer sur les zones exposées une composition comprenant une association d'au moins l'acide nicotinique ou un amide de l'acide nicotinique et d'au moins une base sphingoïde. L'invention a enfin pour objet l'utilisation d'une association d'au moins l'acide nicotinique ou un amide de l'acide nicotinique et d'au moins une base sphingoïde, pour la préparation d'une composition dermatologique destinée à lutter contre l'hyperpigmentation. L' amide d'acide nicotinique peut être de préférence le nicotinamide ou vitamine PP. La base sphingoïde peut être choisie parmi la sphingosine, la sphinganine, la phytosphingosine, la salicyloyl phytosphingosine, le salicylate de phytosphingosine, la tétracétylphytosphingosine, la N-acétyl- phytosphingosine et le chlorhydrate de phytosphingosine.
Suivant l'invention, la base sphingoïde préférée est la phytosphingosine, la salicyloyl phytosphingosine (N-salicyloyl phytosphingosine) ou le chlorhydrate de phytosphingosine. L'acide nicotinique, ou l' amide d'acide nicotinique peut être utilisé à raison de 0,1 à 15 % en poids par rapport au poids total de la composition, et de préférence de 1 à 10 %. La teneur en base sphingoïde peut varier selon la base utilisée, mais elle est généralement comprise entre 0,01 % et 5 %, de préférence entre 0,05 et 2 %. L'acide nicotinique et 1 ' amide d'acide nicotinique, notamment la vitamine PP, ainsi que les bases sphingoïdes utilisées dans les compositions de la présente invention sont généralement disponibles dans le commerce et peuvent être obtenues par des méthodes connues à partir de diverses sources appropriées. Par exemple les bases sphingoïdes peuvent être obtenues à partir de sources naturelles ou par synthèse chimique ou par fermentation. Elles peuvent aussi être obtenues à partir de tissus animaux ou végétaux par extraction et purification. De préférence, les bases sphingoïdes utilisées dans l'invention sont préparées par fermentation microbienne, par exemple à partir d'une levure telle que Pichia ciferii, et la phytosphingosine obtenue de la sorte présente l'avantage d'être très proche de celle de la peau humaine ou animale. Suivant une forme préférentielle de réalisation de l'invention, on utilise comme base sphingoïde la phytosphingosine obtenue à partir de tétra-acétyl-phytosphingosine par desacetylation. La réaction de desacetylation peut s'effectuer par réaction chimique, par exemple par hydrolyse en milieu basique, ou par réaction enzymatique. Les essais effectués sur l'utilisation selon la présente invention des compositions décrites ci-dessus ont mis en évidence une synergie d'action tout particulièrement entre la
vitamine PP et la phytosphingosine, procurant une potentia- lisation de l'activité dépigmentante. La vitamine PP agirait principalement par un mécanisme d'inhibition du transfert de mélanine vers le kératinocyte tandis que la phytosphingosine inhiberait la translocation du NFkappaB après une exposition aux UV. On peut incorporer dans les compositions dont l'utilisation est l'objet de la présente invention un autre agent dépigmentant dont une liste d'exemples a été fournie plus haut en introduction. On peut également associer aux compositions selon la présente invention des exfoliants et notamment l'acide lactique. Toutes ces variantes de compositions font également partie de l'invention. Les excipients et supports utilisables dans les compo- sitions conformes à la présente invention sont ceux couramment utilisés dans les préparations à usage cosmétique, et choisis en fonction de la forme d'administration retenue. A titre d'exemple, on peut citer des gélifiants, des émulsionnants, des épaississants, des conservateurs, des adoucissants, ainsi que des parfums. On peut choisir l'agent émulsionnant parmi des polymères carboxyvinyliques à haut poids moléculaire tels que le Carbopol®, des polysorbates tels que ceux commercialisés sous les marques T een 20® ou Tween 60®, des esters de sorbitan et par exemple un stéarate, un palmitate, un oléate ou un laurate de sorbitan (par exemple l'Arlacel®). On peut encore utiliser comme agents émulsionnants divers dérivés d'acide stéarique ou palmitique tels que le stéarate de glycérol, un stéarate de propylène glycol, un stéarate de polyéthylène glycol, le stéarate de PEG 100®, un stéareth ou un cétéareth, ou encore le polyglycéryl-2-sesquioléate, l'éther cétylique de polyoxy- éthylène, un polyglucoside de siloxane, ou une silicone émul- sionnable.
Les gélifiants et épaississants sont incorporés dans la composition pour en améliorer la fluidité. Ils peuvent être choisis par exemple parmi les polyacrylamides du type Carbopol, les copolymères acrylate/acide acrylique et par exemple l'Aculyn®, les dérivés de cellulose comme 1 'hydroxypropyl cellulose et par exemple le Klucel®, des muco-polysaccharides végétaux, les cires comme la cire d'abeille, les argiles ou les gommes naturelles comme la gomme de xanthane . Les adoucissants peuvent être choisis parmi les alcools gras ou les esters, et par exemple les produits à base d'alcool isostéarylique ou de sorbitol polysaccharidique commercialisés sous les marques Soothex® et Rhamnosoft®. D'une manière générale, les adoucissants usuels de la technique peuvent convenir dans l'invention. Des agents de protection contre les rayons ultra-violets peuvent également être ajoutés aux compositions dont l'utilisation est l'objet de la présente invention. Ces agents de protection peuvent être par exemple des filtres solaires UV-A et UV-B hydrophiles ou lipophiles qui peuvent être choisis parmi la benzophenone ou un dérivé de benzophenone tel que la 2-hydroxy-4-méthoxy-benzophénone (Eusolex® 4360), ou un ester d'acide cinnamique et plus particulièrement le méthoxycinnamate d'octyle (Eusolex® 2292), le méthoxycinnamate d' éthyl-2-hexyle (Parsol MCX®) , ou encore un cyano-β,β-di- phénylacrylate tel que 1 ' octocrylène (Eusolex® OCR), le 4- méthylbenzylidène camphre (Eusolex 6300®) , et des dérivés du dibenzoylméthane tels que le 4-isopropyl dibenzoylméthane (Eusolex 8020) , le t-butyl-méthoxy dibenzoylméthane (ParsolThe present invention The subject of the invention is therefore the use of a composition comprising a combination of at least nicotinic acid or an amide of nicotinic acid and at least one sphingoid base as depigmenting agent . The subject of the invention is also a method of depigmentation of the skin, consisting in applying to the exposed areas a composition comprising a combination of at least nicotinic acid or an amide of nicotinic acid and at least one base. sphingoid. We sometimes speak in the literature for a compound useful in the cosmetic field of "lightning properties- "cissant" for the skin; in the context of the present invention, the "depigmenting properties" include, in addition to the properties making it possible to combat hyperpigmentation, also these "lightening properties". Consequently, the subject of the invention is more particularly the use of a combination of at least nicotinic acid or an amide of nicotinic acid and of at least one sphingoid base to promote lightening of the skin as well as the associated cosmetic treatment method. A more particular subject of the invention is therefore also the use of a combination of at least nicotinic acid or an amide of nicotinic acid and at least one sphingoid base to combat hyperpigmentation of the skin as well as the associated cosmetic treatment method. In other words, the invention also relates to a cosmetic treatment method for the skin intended to reduce, eliminate or avoid pigmentation spots, by providing a depigmenting or lightening effect consisting in applying to the exposed areas a composition comprising a combination of minus nicotinic acid or an amide of nicotinic acid and at least one sphingoid base. A subject of the invention is finally the use of a combination of at least nicotinic acid or an amide of nicotinic acid and at least one sphingoid base, for the preparation of a dermatological composition intended for combating against hyperpigmentation. The nicotinic acid amide may preferably be nicotinamide or vitamin PP. The sphingoid base can be chosen from sphingosine, sphinganine, phytosphingosine, salicyloyl phytosphingosine, phytosphingosine salicylate, tetracetylphytosphingosine, N-acetyl phytosphingosine and phytosphingosine hydrochloride. According to the invention, the preferred sphingoid base is phytosphingosine, salicyloyl phytosphingosine (N-salicyloyl phytosphingosine) or phytosphingosine hydrochloride. The nicotinic acid, or the nicotinic acid amide can be used in an amount of 0.1 to 15% by weight relative to the total weight of the composition, and preferably from 1 to 10%. The sphingoid base content can vary depending on the base used, but it is generally between 0.01% and 5%, preferably between 0.05 and 2%. Nicotinic acid and nicotinic acid amide, especially vitamin PP, as well as the sphingoid bases used in the compositions of the present invention are generally commercially available and can be obtained by known methods from various sources. appropriate. For example, the sphingoid bases can be obtained from natural sources or by chemical synthesis or by fermentation. They can also be obtained from animal or plant tissues by extraction and purification. Preferably, the sphingoid bases used in the invention are prepared by microbial fermentation, for example from a yeast such as Pichia ciferii, and the phytosphingosine obtained in this way has the advantage of being very close to that of the human or animal skin. According to a preferred embodiment of the invention, the phytosphingosine obtained from tetra-acetyl-phytosphingosine by deacetylation is used as the sphingoid base. The deacetylation reaction can be carried out by chemical reaction, for example by hydrolysis in basic medium, or by enzymatic reaction. The tests carried out on the use according to the present invention of the compositions described above have demonstrated a synergy of action, particularly between the vitamin PP and phytosphingosine, providing a potentiation of depigmenting activity. Vitamin PP would act mainly by a mechanism of inhibition of the transfer of melanin towards the keratinocyte while phytosphingosine would inhibit the translocation of NFkappaB after exposure to UV. Another depigmenting agent may be incorporated into the compositions the use of which is the subject of the present invention, a list of examples of which has been provided above in the introduction. It is also possible to combine with the compositions according to the present invention exfoliants and in particular lactic acid. All these variant compositions are also part of the invention. The excipients and carriers which can be used in the compositions in accordance with the present invention are those commonly used in preparations for cosmetic use, and chosen according to the form of administration used. By way of example, mention may be made of gelling agents, emulsifiers, thickeners, preservatives, softeners, as well as perfumes. One can choose the emulsifying agent from carboxyvinyl polymers of high molecular weight such as Carbopol ®, polysorbates such as those marketed under the trademark T een 20 ® or Tween 60 ®, sorbitan esters and, for example a stearate, palmitate, a sorbitan oleate or laurate (for example Arlacel ® ). It is also possible to use, as emulsifying agents, various derivatives of stearic or palmitic acid such as glycerol stearate, propylene glycol stearate, polyethylene glycol stearate, PEG 100® stearate, steareth or ceteareth, or alternatively polyglyceryl-2-sesquioleate, polyoxyethylene cetyl ether, a polyglucoside of siloxane, or an emulsifiable silicone. The gelling agents and thickeners are incorporated into the composition to improve the fluidity. They can be chosen for example from polyacrylamides of the Carbopol type, acrylate / acrylic acid copolymers and for example Aculyn®, cellulose derivatives such as hydroxypropyl cellulose and for example Klucel®, vegetable mucopolysaccharides, waxes like beeswax, clays or natural gums like xanthan gum. The softeners can be chosen from fatty alcohols or esters, and for example products based on isostearyl alcohol or polysaccharide sorbitol sold under the brands Soothex® and Rhamnosoft®. In general, the usual softeners of the technique may be suitable in the invention. Protective agents against ultraviolet rays can also be added to the compositions, the use of which is the subject of the present invention. These protective agents can for example be hydrophilic or lipophilic UV-A and UV-B sun filters which can be chosen from benzophenone or a benzophenone derivative such as 2-hydroxy-4-methoxy-benzophenone (Eusolex® 4360) , or an ester of cinnamic acid and more particularly octyl methoxycinnamate (Eusolex® 2292), ethyl-2-hexyl methoxycinnamate (Parsol MCX®), or alternatively a cyano-β, β-di-phenylacrylate such as octocrylene (Eusolex® OCR), 4-methylbenzylidene camphor (Eusolex 6300®), and dibenzoylmethane derivatives such as 4-isopropyl dibenzoylmethane (Eusolex 8020), t-butyl-methoxy dibenzoylmethane (Parsol
1789®), et le 4-méthoxy-dibenzoylméthane . On peut aussi ajouter aux compositions dont l'utilisation est l'objet de la présente invention des pigments formant un écran anti-ultraviolet, qui peuvent par exemple être choisis parmi le dioxyde de titane (amorphe ou cristallisé sous forme
rutile ou anatase) , l'oxyde de zinc, de zirconium ou encore d'aluminium. On peut en particulier utiliser des nanopigments d'oxydes métalliques de taille de particules comprise entre 5 et 100 nm. Un solvant capable de faciliter ou d'améliorer la pénétration des principes actifs dans la peau peut aussi être avantageusement inclus dans les compositions de l'invention, et par exemple on peut utiliser un dérivé de glycérol amphi- phile non ionique tel que le 1, 2-O-isopropylidèneglycérol (Solketal) . Les compositions pour la mise en œuvre de l'invention peuvent se présenter sous toutes les formes galéniques usuelles adaptées à l'indication dermatologique ou cosméto- logique, pour application topique. Elles peuvent se présenter par exemple sous forme de solutions aqueuses, huileuses ou hydro-alcooliques, de dispersions, de sérums, de gels (aqueux, anhydres ou lipophiles) , de lotions micellaires, de lotions hydro-alcooliques, de solutions pour pulvérisation, de suspensions, de dispersions vésiculaires ioniques ou non ioniques, d'emulsions liquides ou semi-liquides (par exemple un lait), solides ou semi-solides. Les émulsions peuvent être du type huile dans eau (H/E) ou eau dans huile (E/H) , par exemple des gels ou des crèmes. Les compositions dont l'utilisation est l'objet de la présente invention peuvent être appliquées directement sur la peau à raison d'une ou plusieurs applications par jour pendant une durée adaptée à la durée de l'affection. Par exemple, dans le cas du traitement de taches de pigmentation d'intensité moyenne chez un sujet de 50 à 60 ans, de bons résultats peuvent être obtenus en appliquant une composition suivant l'invention deux fois par jour pendant une période ininterrompue de 6 à 8 semaines.
Les exemples qui suivent illustrent la présente invention, sans toutefois la limiter.1789®), and 4-methoxy-dibenzoylmethane. It is also possible to add to the compositions the use of which is the subject of the present invention pigments forming an anti-ultraviolet screen, which can for example be chosen from titanium dioxide (amorphous or crystallized in the form rutile or anatase), zinc oxide, zirconium or aluminum. In particular, nanopigments of metal oxides with a particle size between 5 and 100 nm can be used. A solvent capable of facilitating or improving the penetration of the active principles into the skin can also advantageously be included in the compositions of the invention, and for example one can use a non-ionic amphiphilic glycerol derivative such as 1, 2-O-isopropylidene glycerol (Solketal). The compositions for implementing the invention can be in all the usual dosage forms suitable for dermatological or cosmetic indication, for topical application. They can be, for example, in the form of aqueous, oily or hydroalcoholic solutions, dispersions, sera, gels (aqueous, anhydrous or lipophilic), micellar lotions, hydroalcoholic lotions, spray solutions, suspensions, ionic or nonionic vesicular dispersions, liquid or semi-liquid emulsions (for example milk), solid or semi-solid. The emulsions can be of the oil in water (O / W) or water in oil (W / O) type, for example gels or creams. The compositions, the use of which is the subject of the present invention, can be applied directly to the skin at the rate of one or more applications per day for a duration adapted to the duration of the affection. For example, in the case of the treatment of pigmentation spots of medium intensity in a subject 50 to 60 years old, good results can be obtained by applying a composition according to the invention twice a day for an uninterrupted period of 6 to 8 weeks. The examples which follow illustrate the present invention, without however limiting it.
Exemple 1 Une étude en aveugle sur des volontaires a été réalisée en période ensoleillée (8 volontaires par produit) . Cette étude repose sur une évaluation globale des paramètres de couleur de la peau dorsale des mains sur un mode « avant » versus « après » utilisation. Les produits ont été appliqués sur l'ensemble de la main et l'effet a été évalué au niveau de taches pigmentaires pré-sélectionnées et au niveau d'une zone ne présentant pas de tache (dénommée site « témoin ») . Chaque volontaire a utilisé une crème de protection solaire sur les mains afin de minimiser le risque d'une hyperpigmentation susceptible d'apparaître sous l'influence des rayonnements ultraviolets liés à l'ensoleillement durant l'expérimentation. Les paramètres suivants ont été étudiés : géométrie des taches (taille) , indice mélanique sur la tache et sur le site « témoin » et, - luminance (L*) sur la tache et sur le site « témoin ». L'analyse concerne l'évolution des paramètres entre le premier et le dernier jour de l'étude pour les produits appliqués . La composition des produits étudiés est la suivante :Example 1 A blind study on volunteers was carried out during the sunny period (8 volunteers per product). This study is based on a global evaluation of the color parameters of the back skin of the hands in a “before” versus “after” use mode. The products were applied to the entire hand and the effect was evaluated at the level of pre-selected pigment spots and at the level of an area free from stains (called the "control" site). Each volunteer used a sun protection cream on the hands to minimize the risk of hyperpigmentation which could appear under the influence of ultraviolet radiation linked to sunlight during the experiment. The following parameters were studied: geometry of the spots (size), melanic index on the spot and on the "control" site and, - luminance (L *) on the spot and on the "control" site. The analysis concerns the evolution of the parameters between the first and the last day of the study for the applied products. The composition of the products studied is as follows:
Vitaminé PP Dépigmentant Formule 1 0 g, o 0 % Formule 2 5 Q. 0 Salicyloyl Phytosphingosine 0, 1% Formule 3 5 g. Ό Formule 4 0 o. o Arlatone dioïc Formule 5 0 Ό Albatin
Ainsi, la formule 1 est la formule placebo, la formule 2 repose sur la « base active » contenant de la vitamine PP à la concentration de 5 %, dans laquelle une base sphingoïde a été ajoutée, tandis que la formule 3 contient la même dose de vitamine PP sans phytosphingosine. Les formules 4 et 5 sont des compositions disponibles dans le commerce contenant des dépigmentants répertoriés, à savoir l'acide octadécène dioïque (Arlatone dioic) et l'acide aminoéthylphosphinique (Albatin) . Les résultats obtenus montrent que : - Pour les formulations 1, 2 et 3, la géométrie des taches n'évolue pas significativement au cours du temps. - La luminance (L*) de la peau augmente (la couleur de la peau s'éclaircit) au niveau des taches et au niveau de la zone « témoin » pour la formule 2. - L'indice melanique diminue (moins de mélanine est présente) au niveau de la tache et au niveau de la zone « témoin » pour la formule 2. Pour la formule placebo (formule 1) et pour la formule 3 contenant de la vitamine PP sans phytosphingosine, au cours du temps, l'indice melanique augmente notablement et de manière comparable malgré l'usage du produit solaire. Il en est de même pour les formules 4 et 5 qui n'ont pas d'incidence sensible sur l'indice melanique et sur la luminance. Par contre, lors de l'utilisation de la formule 2, on observe une diminution de cet indice melanique. La diminution observée est plus intense sur les taches pigmentaires qu'au niveau de la « zone témoin ». Il faut également souligner que 63% des volontaires (5 sur 8) ont signalé pour la formule 2 une diminution de la couleur des taches qui est cotée « oui, nettement », et « oui, probablement ».
Globalement cette étude confirme l'intérêt de l'association vitamine PP et Salicyloyl Phytosphingosine 0,1 % à titre d'agent dépigmentant. De plus, une étude comparative de l'activité antityro- sinase a permis de mettre en évidence la potentialisation de l'effet dépigmentant résultant de la combinaison de la vitamine PP et de la phytosphingosine. L'activité antityrosinase est reconnue comme un indicateur in vitro de l'activité dépigmentante d'une composition. Les essais sont effectués en comparant deux formules dépigmentantes connues disponibles dans le commerce (A et B) et une formule conforme à l'invention (formule C) : Formule A : composition du commerce (TRIO D®) Formule B : composition du commerce (TRIO A®) Formule C : identique à l'Exemple 5 ci-dessous Le TRIO D est une composition dépigmentante à base de lactate d'ammonium, d'acide ascorbique et de glabridine à la concentration de 0,1%. Le TRIO A comprend les mêmes principes actifs et de la glabridine à la concentration de 0,2%. La formule C de l'invention contient la même concentration de glabridine, qui est un composé connu pour son activité antityrosinase. Les essais. sont effectués suivant les techniques classiques de mesure, les compositions étant en solution ethanolique tamponnée à pH 6,8 contenant 500 μl de solution de tyrosine et 500 μl de solution de tyrosinase, et le témoin utilisé est identique mais ne contient pas de dépigmentant. Un blanc témoin est identique au témoin mais la tyrosinase est remplacée par une même quantité d'eau. De même un blanc essai est préparé en utilisant le même échantillon de formule à tester mais en remplaçant la tyrosinase par une même quantité d'eau.
On laisse incuber 1 heure au bain-marie à 37 °C à l'abri de la lumière puis on refroidit les tubes contenant les formules testées sur bain d'eau froide à environ 18 °C. L'absorbance des solutions est mesurée à 475 n en cuve de 10 mm. Les résultats sont regroupés au tableau suivant.Vitamin PP Depigmenting Formula 1 0 g, 0% Formula 2 5 Q. 0 Salicyloyl Phytosphingosine 0, 1% Formula 3 5 g. Ό Formula 4 0 o. o Arlatone dioïc Formula 5 0 Ό Albatin Thus, formula 1 is the placebo formula, formula 2 is based on the “active base” containing vitamin PP at a concentration of 5%, in which a sphingoid base has been added, while formula 3 contains the same dose of vitamin PP without phytosphingosine. Formulas 4 and 5 are commercially available compositions containing listed depigmentants, namely octadecene dioic acid (Arlatone dioic) and aminoethylphosphinic acid (Albatin). The results obtained show that: - For formulations 1, 2 and 3, the geometry of the spots does not change significantly over time. - The luminance (L *) of the skin increases (the color of the skin becomes lighter) at the level of the spots and at the level of the “control” zone for formula 2. - The melanic index decreases (less melanin is present) at the spot level and at the level of the "control" zone for formula 2. For the placebo formula (formula 1) and for the formula 3 containing vitamin PP without phytosphingosine, over time, the index melanique increases notably and in a comparable way in spite of the use of the solar product. The same is true for formulas 4 and 5 which have no appreciable effect on the melanic index and on the luminance. On the other hand, when using formula 2, a decrease in this melanic index is observed. The decrease observed is more intense on the pigment spots than in the "control zone". It should also be noted that 63% of volunteers (5 out of 8) reported for formula 2 a decrease in the color of the spots, which is rated "yes, clearly", and "yes, probably". Overall, this study confirms the interest of the association vitamin PP and Salicyloyl Phytosphingosine 0.1% as depigmenting agent. In addition, a comparative study of the antityro-sinase activity made it possible to highlight the potentiation of the depigmenting effect resulting from the combination of vitamin PP and phytosphingosine. The antityrosinase activity is recognized as an in vitro indicator of the depigmenting activity of a composition. The tests are carried out by comparing two depigmenting formulas known commercially available (A and B) and a formula in accordance with the invention (formula C): Formula A: commercial composition (TRIO D ® ) Formula B: commercial composition ( TRIO A ® ) Formula C: identical to Example 5 below TRIO D is a depigmenting composition based on ammonium lactate, ascorbic acid and glabridin at a concentration of 0.1%. TRIO A includes the same active ingredients and glabridin at a concentration of 0.2%. Formula C of the invention contains the same concentration of glabridin, which is a compound known for its antityrosinase activity. Attempts. are carried out according to conventional measurement techniques, the compositions being in ethanolic solution buffered to pH 6.8 containing 500 μl of tyrosine solution and 500 μl of tyrosinase solution, and the control used is identical but does not contain depigmentant. A blank control is identical to the control but the tyrosinase is replaced by the same amount of water. Similarly, a blank test is prepared using the same sample of formula to be tested but by replacing the tyrosinase with the same amount of water. It is left to incubate for 1 hour in a water bath at 37 ° C protected from light and then the tubes containing the formulas tested are cooled in a cold water bath to about 18 ° C. The absorbance of the solutions is measured at 475 n in a 10 mm tank. The results are collated in the following table.
Le taux moyen d'inhibition pour une quantité de produit de lmg a été obtenu en faisant la moyenne des mesures de chaque formule (3 mesures par formule) rapportée à une quantité de produit de 1 mg. On constate donc que la formule C selon l'invention présente une activité antityrosinase notablement plus élevée que les formules de référence, entraînant un pouvoir dépigmen- tant plus important. On constate en particulier que le taux d'inhibition est doublé par rapport à la formule B qui contient la même teneur en glabridine. Ceci démontre l'effet de l'association de vitamine PP et de phytosphingosine sur la dépigmentation . Les exemples qui suivent ont trait à des formulations contenant une association dont l'utilisation est objet de la présente demande de brevet. Les noms des composants sont issus de la nomenclature INCI .
Exemple 2 EMULSION DEPIGMENTANTEThe average inhibition rate for an amount of lmg product was obtained by averaging the measurements of each formula (3 measurements per formula) compared to an amount of product of 1 mg. It is therefore found that the formula C according to the invention has a significantly higher antityrosinase activity than the reference formulas, resulting in a greater depigmatory power. It is noted in particular that the inhibition rate is doubled compared to formula B which contains the same glabridin content. This demonstrates the effect of the combination of vitamin PP and phytosphingosine on depigmentation. The examples which follow relate to formulations containing an association the use of which is the subject of the present patent application. The names of the components are taken from the INCI nomenclature. EXAMPLE 2 DEPIGMENTING EMULSION
Capric/càprylic triglycéride 5, .00%Capric / càprylic triglyceride 5, .00%
PPG-15 stearyl ether 5, .00% Arachidyl alcohol (et) behenyl alcoholPPG-15 stearyl ether 5, .00% Arachidyl alcohol (et) behenyl alcohol
(et) arachidyl glucoside 3, .00% salicyloyl phytosphingosine o, .10%(and) arachidyl glucoside 3, .00% salicyloyl phytosphingosine o, .10%
PEG-100 stéarate (et) glyceryl stéarate 1, .50%PEG-100 stearate (and) glyceryl stearate 1, .50%
Cethyl alcohol 1, .00% Dimethicone 11 .00%Cethyl alcohol 1, .00% Dimethicone 11 .00%
Aqua qsp 100Aqua qs 100
Xanthane Gum o, .30%Xanthane Gum o, .30%
Conservateurs qspPreservatives qs
Parfum qsp Nicotinamide 5, ,00%Perfume qs Nicotinamide 5, 00%
Acide Lactique 5, ,00%Lactic Acid 5, .00%
Base qsp pH= =4,5Base qs pH = = 4.5
Exemple 3 EMULSION DEPIGMENTANTE Capric/caprylic triglycéride 5,00%EXAMPLE 3 DEPIGMENTING EMULSION Capric / caprylic triglyceride 5.00%
PPG-15 stearyl ether 5,00%PPG-15 stearyl ether 5.00%
Isopropyl palmitate 4,00% salicyloyl phytosphingosine 0,10% steareth-2 3,00% steareth-21 2,00%Isopropyl palmitate 4.00% salicyloyl phytosphingosine 0.10% steareth-2 3.00% steareth-21 2.00%
PEG-100 stéarate (et) glyceryl stéarate 1,00%PEG-100 stearate (and) glyceryl stearate 1.00%
Cetyl alcohol 1,00%Cetyl alcohol 1.00%
Dimethicone 1,00%Dimethicone 1.00%
Aqua qsp 100 Xanthane Gum 0,30%Aqua qsp 100 Xanthane Gum 0.30%
Conservateurs qspPreservatives qs
Parfum qspPerfume qs
Glabridine 0,20%
Nicotinamide 5,00%Glabridin 0.20% Nicotinamide 5.00%
Undecylanoyl phenylalanine 2,00%Undecylanoyl phenylalanine 2.00%
Acide/base qsp pH=4,5Acid / base qs pH = 4.5
Exemple 4 GEL ALCOOLIQUEEXAMPLE 4 ALCOHOLIC GEL
Alcool qsp 100Alcohol qs 100
Cyclopentasiloxane 13,00%Cyclopentasiloxane 13.00%
Propylène glycol 16,00%Propylene glycol 16.00%
Nicotinamide 4,00% C12/15 alkyl benzoate 12,00%Nicotinamide 4.00% C12 / 15 alkyl benzoate 12.00%
Glabridine 0,20%Glabridin 0.20%
Salicyloyl phytosphingosine 0,20%Salicyloyl phytosphingosine 0.20%
Exemple 5 SOLUTION Capric/caprylic triglycéride 12,00%EXAMPLE 5 SOLUTION Capric / caprylic triglyceride 12.00%
Solketal 48,00%Solketal 48.00%
Phytosphingosine 0,10%Phytosphingosine 0.10%
Nicotinamide 5,00%Nicotinamide 5.00%
Alcool qsp 100
Alcohol qs 100
Claims
1. Utilisation d'une composition comprenant une association d'au moins l'acide nicotinique ou un amide de l'acide nicotinique et d'au moins une base sphingoïde à titre d'agent dépigmentant. - 2. Utilisation selon la revendication 1, caractérisée en ce que la base sphingoïde est choisie parmi la sphingosine, la sphinganine, la phytosphingosine, la salicyloyl phytosphingosine, le salicylate de phytosphingosine, la tétracétyl- phytosphingosine, la N-acétylphytosphingosine et le chlorhy- drate de phytosphingosine. 3. Utilisation selon la revendication 2, caractérisée en ce que la base sphingoïde est choisie parmi la phytosphingosine, la salicyloyl phytosphingosine ou le chlorhydrate de phytosphingosine. 4. Utilisation selon l'une quelconque des revendications 1 à 3, caractérisée en ce que 1 ' amide d'acide nicotinique est le nicotinamide. 5. Utilisation selon l'une quelconque des revendications 1 à 4, caractérisée en ce que la teneur en base sphingoïde dans la composition est comprise entre 0,01 % et 5 % par rapport au poids total de la composition. 6. Utilisation selon la revendication 5, caractérisée en ce que la teneur en base sphingoïde est comprise entre 0,05 % et 2 % .par rapport au poids total de la composition. 7. Utilisation selon l'une quelconque des revendications 1 à 6, caractérisée en ce que la teneur en acide nicotinique, ou en amide d'acide nicotinique, dans la composition est comprise entre 0,1 et 15 % en poids par rapport au poids total de la composition. 8. Utilisation selon la revendication 7, caractérisée en ce que la teneur en acide nicotinique, ou en amide d'acide nicotinique, dans la composition est comprise entre 1 et 10 % en poids par rapport au poids total de la composition. 9. Utilisation selon l'une quelconque des revendications 1 à 8 pour favoriser l'éclaircissement de la peau. 10. Utilisation selon l'une quelconque des revendications 1 à 8 pour lutter contre l'hyperpigmentation. 11. Méthode de traitement cosmétique de la peau destinée à réduire, supprimer ou éviter les tâches de pigmentation, en procurant un effet dépigmentant consistant à appliquer sur les zones exposées une composition telle que définie dans l'une quelconque des revendications 1 à 8. 12. Méthode de traitement cosmétique selon la revendication 11, caractérisée en ce qu'elle est destinée à favoriser l'éclaircissement de la peau. 13. Méthode de traitement cosmétique selon la revendication 11, caractérisée en ce qu'elle est destinée à lutter contre l'hyperpigmentation de la peau. 14. Utilisation d'une composition telle que définie dans l'une quelconque des revendications 1 à 8 pour la préparation ' d'une composition dermatologique destinée à lutter contre l' hyperpigmentation . 1. Use of a composition comprising a combination of at least nicotinic acid or an amide of nicotinic acid and at least one sphingoid base as depigmenting agent. - 2. Use according to claim 1, characterized in that the sphingoid base is chosen from sphingosine, sphinganine, phytosphingosine, salicyloyl phytosphingosine, phytosphingosine salicylate, tetracetyl-phytosphingosine, N-acetylphytosphingosine and chlorhy- phytosphingosine drate. 3. Use according to claim 2, characterized in that the sphingoid base is chosen from phytosphingosine, salicyloyl phytosphingosine or phytosphingosine hydrochloride. 4. Use according to any one of claims 1 to 3, characterized in that the nicotinic acid amide is nicotinamide. 5. Use according to any one of claims 1 to 4, characterized in that the content of sphingoid base in the composition is between 0.01% and 5% relative to the total weight of the composition. 6. Use according to claim 5, characterized in that the content of sphingoid base is between 0.05% and 2% . relative to the total weight of the composition. 7. Use according to any one of claims 1 to 6, characterized in that the content of nicotinic acid, or of nicotinic acid amide, in the composition is between 0.1 and 15% by weight relative to the weight total of the composition. 8. Use according to claim 7, characterized in that the content of nicotinic acid, or of acid amide nicotinic, in the composition is between 1 and 10% by weight relative to the total weight of the composition. 9. Use according to any one of claims 1 to 8 to promote lightening of the skin. 10. Use according to any one of claims 1 to 8 for combating hyperpigmentation. 11. Cosmetic treatment method for the skin intended to reduce, eliminate or avoid pigmentation spots, by providing a depigmenting effect consisting in applying to the exposed areas a composition as defined in any one of claims 1 to 8. 12 Cosmetic treatment method according to claim 11, characterized in that it is intended to promote lightening of the skin. 13. Cosmetic treatment method according to claim 11, characterized in that it is intended to combat hyperpigmentation of the skin. 14. Use of a composition as defined in any one of claims 1 to 8 for the preparation of a dermatological composition intended to combat hyperpigmentation.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0403740A FR2868702B1 (en) | 2004-04-09 | 2004-04-09 | USE OF A SPHINGOID BASE ASSOCIATED WITH NICOTINIC ACID OR AN AMIDE OF NICOTINIC ACID AS DEPIGMENTING AGENT |
| PCT/FR2005/000864 WO2005102337A2 (en) | 2004-04-09 | 2005-04-08 | Use of a sphingoid base associated with nicotinic acid or a nicotinic acid amide in the form of a depigmentation agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP1737457A2 true EP1737457A2 (en) | 2007-01-03 |
Family
ID=34944649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP05753773A Withdrawn EP1737457A2 (en) | 2004-04-09 | 2005-04-08 | Use of a sphingoid base associated with nicotinic acid or a nicotinic acid amide in the form of a depigmentation agent |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20070238764A1 (en) |
| EP (1) | EP1737457A2 (en) |
| JP (1) | JP2007532521A (en) |
| CA (1) | CA2561393A1 (en) |
| FR (1) | FR2868702B1 (en) |
| WO (1) | WO2005102337A2 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2823671B1 (en) * | 2001-04-23 | 2004-01-09 | Dermaconcept Jmc | DERMATOLOGICAL COMPOSITION COMPRISING NICOTINIC ACID OR AN AMIDE, AND A SPHINGOID BASE |
| FR2894961B1 (en) * | 2005-12-16 | 2008-05-16 | Oreal | USE OF CERAMIDES FOR DEPIGMENTING THE SKIN |
| FR2906143B1 (en) * | 2006-09-21 | 2010-01-22 | Etienne Pierre Dominiq Soudant | COSMETIC, PHARMACEUTICAL AND DERMATOLOGICAL BINARY TREATMENT METHOD FOR SYNCHRONIZING OR RESYNCHRONIZING THE SKIN AND THE WHOLE ORGANISM |
| FR2906139A1 (en) * | 2006-09-21 | 2008-03-28 | Davines France Sarl | Binary treatment to fight against the signs of skin aging and to eliminate undesirable cell growth, comprises applying a night formulation to stimulate and/or activate sirtuins and applying a day formulation to inhibit the same sirtuins |
| EP2448548B1 (en) * | 2010-07-22 | 2017-03-01 | The Procter and Gamble Company | Method for improving the appearance of hyperpigmented spot(s) using an extract of laminaria saccharina |
| JP5726481B2 (en) * | 2010-10-29 | 2015-06-03 | 日本精化株式会社 | Cosmetic or skin external preparation containing hydroxynicotinic acid or a derivative thereof |
| DE102011109546A1 (en) * | 2011-08-03 | 2013-02-07 | Evonik Goldschmidt Gmbh | Use of sphinganine to improve the visual appearance of the skin and hair |
| MY195546A (en) * | 2018-03-09 | 2023-01-31 | Ocusoft Inc | Topical Skin Care Compositions |
| FR3100129A1 (en) * | 2019-08-26 | 2021-03-05 | Laboratoire Promicea | New anti-hyperpigmentation spot composition |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1370236A (en) * | 1972-01-11 | 1974-10-16 | Unilever Ltd | Skin composition |
| GB1533119A (en) * | 1975-04-10 | 1978-11-22 | Unilever Ltd | Skin lightening compositions |
| US5882665A (en) * | 1997-11-18 | 1999-03-16 | Elizabeth Arden Co., Division Of Conopco, Inc. | Phytosphingosine salicylates in cosmetic compositions |
| WO1999047114A1 (en) * | 1998-03-16 | 1999-09-23 | The Procter & Gamble Company | Moisturizing compositions |
| JP2001010926A (en) * | 1999-06-28 | 2001-01-16 | Kao Corp | Bleaching agent |
| FR2823671B1 (en) * | 2001-04-23 | 2004-01-09 | Dermaconcept Jmc | DERMATOLOGICAL COMPOSITION COMPRISING NICOTINIC ACID OR AN AMIDE, AND A SPHINGOID BASE |
-
2004
- 2004-04-09 FR FR0403740A patent/FR2868702B1/en not_active Expired - Fee Related
-
2005
- 2005-04-08 WO PCT/FR2005/000864 patent/WO2005102337A2/en active Application Filing
- 2005-04-08 CA CA002561393A patent/CA2561393A1/en not_active Abandoned
- 2005-04-08 US US11/547,846 patent/US20070238764A1/en not_active Abandoned
- 2005-04-08 EP EP05753773A patent/EP1737457A2/en not_active Withdrawn
- 2005-04-08 JP JP2007506814A patent/JP2007532521A/en active Pending
Non-Patent Citations (1)
| Title |
|---|
| See references of WO2005102337A2 * |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2868702B1 (en) | 2006-12-22 |
| WO2005102337A3 (en) | 2005-12-29 |
| CA2561393A1 (en) | 2005-11-03 |
| WO2005102337A2 (en) | 2005-11-03 |
| JP2007532521A (en) | 2007-11-15 |
| US20070238764A1 (en) | 2007-10-11 |
| FR2868702A1 (en) | 2005-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2174598C (en) | Use of an inhibitor of an hmg-coenzyme-a reductase to prevent aging of the skin or to stimulate the process of epidermal renewal | |
| EP1021161B1 (en) | Use of ellagic acid and its derivatives in cosmetics and dermatology | |
| EP0747043B1 (en) | Use of salicylic acid derivatives for skin whitening | |
| EP1737457A2 (en) | Use of a sphingoid base associated with nicotinic acid or a nicotinic acid amide in the form of a depigmentation agent | |
| EP1962788B1 (en) | Use of ceramides and salicylic acid derivatives for depigmenting the skin | |
| FR2950805A1 (en) | USE OF VANILLIN DERIVATIVES AS A PRESERVATIVE, METHOD OF PRESERVATION, COMPOUNDS AND COMPOSITION | |
| EP1269986B1 (en) | Compositions comprising a compound of low solubility and a lipophilic amino acid derivative, and corresponding uses and processes | |
| FR3115207A1 (en) | Use of thiopyridinone compounds to prevent the formation of cutaneous blackheads | |
| EP3364964B1 (en) | Composition based on dihydromyricetin and a zinc salt for the treatment of acne and oily skin | |
| FR2949065A1 (en) | SKIN LIGHTENING COMPLEX, USE OF SAID COMPLEX, COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPLEX AND METHOD FOR APPLICATION THEREOF | |
| FR2921254A1 (en) | Cosmetic use of ascorbic acid in combination with jasmonic acid derivative, to prepare a composition for depigmenting and/or bleaching of skin, to reduce or eliminate the pigmentation, and/or to reduce the size of the lentigo | |
| EP0756866B1 (en) | Use of benzoic acid derivatives for stimulating the renewal of the epidermis and for treating the skin | |
| FR2849597A1 (en) | Cosmetic composition for treating greasy skin, contains a dicarboxylic fatty acid or derivative, reduces secretion of sebum and inhibits lipogenesis | |
| EP2694027B1 (en) | Use of (ethoxy-hydroxy phenyl)alkyl ketone or ethoxy hydroxy alkyl phenol compounds for treating oily skin | |
| US11918666B2 (en) | Topical formulations comprising strontium and methylsulfonylmethane (MSM) and methods of treatment | |
| WO2015118281A1 (en) | Composition for controlling hair loss | |
| FR2993775A1 (en) | Cosmetic composition, useful for depigmenting skin exposed to sun, comprises a synergistic combination of a melanogenesis inhibitor of resorcinol, a stable antioxidant derived from oxidation of ascorbic acid and rhubarb root extract | |
| EP0940140A1 (en) | Topical composition of alpha hydroxy acids and ceramides for the treatment of skin conditions | |
| FR2894141A1 (en) | SKIN DEPIGMENTING COMPOSITION COMPRISING A NAPHTHOTIC ACID DERIVATIVE | |
| CA2511901A1 (en) | Cosmetic composition for greasy skin care, containing a carboxylic fatty acid or a derivative thereof | |
| FR3060358A1 (en) | COMPOSITION COMPRISING BAICALIN, A FATTY ACID ESTER AND ALKYLPOLYGLYCOSIDE | |
| FR2903901A1 (en) | Use of calcium channel antagonists as cosmetic skin lightening and/or antitanning agents | |
| CA3177115A1 (en) | Stabilized cosmetic compositions with n, n'-diacetyl cystine | |
| FR3132638A1 (en) | Use of rhamnolipid(s) to prevent staining of cutaneous blackheads | |
| FR3082121A1 (en) | NEW COMPLEX OF DEPIGMENTING ASSETS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20061021 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: LEFEVRE, JEAN-MARIE Inventor name: ALLART, JEAN-CLAUDE Inventor name: PEYROT, JACQUES |
|
| 17Q | First examination report despatched |
Effective date: 20070515 |
|
| DAX | Request for extension of the european patent (deleted) | ||
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20090810 |